Table 2 Baseline characteristics

Pre-existing eye disease

11 (4 documented as mild/inactive)

Duration of Medical Treatment (months)

24 (3 weeks to 12 years)

Technetium uptake (%)

4.3 (0.8–66)

TSH receptor antibody (IU/L)

8 (0–240)

Smoker (documented)

15

Glucocorticoid cover with pre-existing eye disease

7